Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster

Biochemical Pharmacology

Volumn 68, Issue 12, 2004, Pages 2301-2315

  De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Brivudin; DNA polymerase; Herpes zoster

Indexed keywords

3' O BENZYL 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 (2 BROMOVINYL 2' DEOXYURIDINE; 5 (2 BROMOVINYL) 1 [3 DEOXY 3 C (HYDROXYMETHYL) BETA DEXTRO ARABINOPENTOFURANOSYL]URACIL; 5 (2 BROMOVINYL) 1 [TETRAHYDRO 4,5 BIS(HYDROXYMETHYL) 3 FURANYL 2,4(1H,3H) PYRIMIDINEDIONE; 5 (2 BROMOVINYL) 1 [[1',2' BIS(HYDROXYMETHYL)CYCLOPROPYL]METHYL] 2,4(1H,3H) PYRIMIDINEDIONE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 (2 BROMOVINYL)URACIL; ACICLOVIR; ANTIVIRUS AGENT; BRIVIRAC; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA POLYMERASE; FAMCICLOVIR; FLUOROURACIL; GANCICLOVIR; IDOXURIDINE; PENCICLOVIR; PYRIMIDINE DERIVATIVE; SORIVUDINE; TEGAFUR; THYMIDINE KINASE; TRIFLURIDINE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; URIDINE DERIVATIVE; VALACICLOVIR; VIDARABINE; VIRUS DNA; ZERPEX; ZOSTEX;

BONE MARROW TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME INHIBITION; EUROPE; GASTROINTESTINAL TOXICITY; GERMANY; HERPES SIMPLEX VIRUS 1; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENCE; ITALY; KERATITIS; LEUKOPENIA; LICENSING; NONHUMAN; PATIENT; PHOSPHORYLATION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION;

EID: 7544248773     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.07.039     Document Type: Article

References (119)

1. E. De Clercq, J. Descamps, P.J. Barr, A.S. Jones, P. Serafinowski, and R.T. Walker Comparative study of the potency and selectivity of anti-herpes compounds J. Skoda P. Langen Antimetabolites in biochemistry, biology and medicine 1979 Pergamon Press Oxford 275 285
2. R.T. Walker, P.J. Barr, E. De Clercq, J. Descamps, A.S. Jones, and P. Serafinowski The synthesis and properties of some antiviral nucleosides Nucl. Acids Res 1978 103 106 special publication no 4
3. E. De Clercq, J. Descamps, P. De Somer, P.J. Barr, A.S. Jones, and R.T. Walker (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent Proc Natl Acad Sci USA 76 1979 2947 2951
4. D. Bärwolff, and P. Langen A selective bromination of thymidine Nucl. Acids Res 1975 s29 s31 special publication no 1
5. J. Reefschläger, D. Bärwolff, P. Engelmann, P. Langen, and H.A. Rosenthal Efficiency and selectivity of (E)-5-(2-bromovinyl)-2′- deoxyuridine and some other 5-substituted 2′-deoxypyrimidine nucleosides as anti-herpes agents Antiviral Res 2 1982 41 52
6. G.B. Elion, P.A. Furman, J.A. Fyfe, P. de Miranda, L. Beauchamp, and H.J. Schaeffer Selectivity of action of an antiherpetic agent, 9-(2- hydroxyethoxymethyl)guanine Proc Natl Acad Sci USA 74 1977 5716 5720
7. H.J. Schaeffer, L. Beauchamp, P. de Miranda, G.B. Elion, D.J. Bauer, and P. Collins 9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group Nature 272 1978 583 585
8. K.A. Watanabe, U. Reichman, K. Hirota, C. Lopez, and J.J. Fox Nucleosides. 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′-deoxyarabinofuranosyl-pyrimidine nucleosides J Med Chem 22 1979 21 24
9. C. Lopez, K.A. Watanabe, and J.J. Fox 2′-Fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent Antimicrob Agents Chemother 17 1980 803 806
10. De Clercq E. Antiviral agents. In: Greenwood, D., O'Grady, F, editors. Symposium of the Society for General Microbiology. Scientific Basis of Antimicrobial Chemotherapy. Cambridge: Cambridge University Press; 1985, p. 155-84.
11. E. De Clercq Antiviral and antitumor activities of 5-substituted 2′-deoxyuridines Meth Find Exptl Clin Pharmacol 2 1980 253 267
12. De Clercq E, Antiviral activity of pyrimidine nucleoside analogs: a structure-function analysis. In: Alderweireldt FC, Esmans EL, editors. Proceedings of the Fourth International Round Table on Nucleosides, Nucleotides and their Biological Applications, Antwerp, 4-6 February 1981. Antwerp: The University of Antwerp; 1982, 25-45.
13. E. De Clercq Selective antiherpes agents Trends Pharmacol Sci 3 1982 492 495
14. E. De Clercq Antiviral activity of 5-substituted pyrimidine nucleoside analogues Pure Appl Chem 55 1983 623 636
15. E. De Clercq The chemotherapy of herpesvirus infections with reference to bromovinyldeoxyuridine and other antiviral compounds C.H. Stuart-Harris J. Oxford Problems of antiviral therapy 1983 Academic Press London 295 315
16. E. De Clercq Bromovinyldeoxyuridine (BVDU): current status in antiviral therapy E. Kurstak Control of virus diseases 1984 Marcel Dekker, Inc. New York 443 458
17. E. De Clercq Therapeutic potentials of bromovinyldeoxyuridine (BVDU) in the treatment of herpesvirus infections. I. Fundamental aspects F. Rapp Herpesvirus 1984 Alan R. Liss, Inc. New York 573 585
18. E. De Clercq Therapeutic potentials of bromovinyldeoxyuridine (BVDU) in the treatment of herpesvirus infections. I. Clinical aspects F. Rapp Herpesvirus 1984 Alan R. Liss, Inc. New York 587 599
19. E. De Clercq Synthetic pyrimidine nucleoside analogues M.R. Harnden Approaches to antiviral agents 1985 MacMillan Press London 57 99
20. E. De Clercq Towards a selective chemotherapy of virus infections. Development of bromovinyldeoxyuridine as a highly potent and selective antiherpetic drug Verh K Acad Geneesk Belg 48 1986 261 290
21. E. De Clercq, G. Verhelst, J. Descamps, and D.E. Bergstrom Differential inhibition of herpes simplex viruses, type 1 (HSV-1) and type 2 (HSV-2), by (E)-5-(2-X-vinyl)-2′-deoxyuridines Acta microbiol Acad Sci hung 28 1981 307 312
22. E. De Clercq, C. Desgranges, P. Herdewijn, I.S. Sim, and R.T. Walker Bromovinyluracil nucleoside analogues as antiherpes agents R. Dahlbom Nilsson JLG Proceedings of the VHIth International Symposium on Medicinal Chemistry, vol. 1 1985 Swedish Pharmaceutical Press Stockholm 198 210
23. E. De Clercq, and R.T. Walker Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs Pharmac Ther 26 1984 1 44
24. E. De Clercq, and R.T. Walker Chemotherapeutic agents for herpesvirus infections G.P. Ellis G.B. West Progress in medicinal chemistry 23 1986 Elsevier Science Publishers, B.V Amsterdam 187 218
25. E. De Clercq, J. Descamps, G. Verhelst, R.T. Walker, A.S. Jones, and P.F. Torrence Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus J Infect Dis 141 1980 563 574
26. S. Shigeta, T. Yokota, T. Iwabuchi, M. Baba, K. Konno, and M. Ogata Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus J Infect Dis 147 1983 576 584
27. E. De Clercq, H. Degreef, J. Wildiers, G. de Jonge, A. Drochmans, and J. Descamps Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine in severe herpes zoster Br Med J 281 1980 1178
28. P.C. Maudgal, L. Missotten, E. De Clercq, J. Descamps, and E. De Meuter Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the topical treatment of herpes simplex keratitis Albrecht von Graefes Arch Klin Ophthalmol 216 1981 261 268
29. J. Wildiers, and E. De Clercq Oral (E)-5-(2-bromovinyl)-2′- deoxyuridine treatment of severe herpes zoster in cancer patients Eur J Cancer Clin Oncol 20 1984 471 476
30. Y. Benoit, G. Laureys, M-J. Delbeke, and E. De Clercq Oral BVDU treatment of varicella and zoster in children with cancer Eur J Pediatr 143 1985 198 202
31. P.C. Maudgal, and E. De Clercq Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents Curr Eye Res 10 Suppl 1991 193 199
32. H. Töpke, J. Reefschläger, D. Bärwolff, and C. Halibrand Erste Erfahrungen mit dem Antiherpetikum (E)-5-(2-Bromvinyl)-2′- Desoxyuridin (BrVUdR) bei der Behandlung des Herpes corneae Folia ophthal 9 1984 39 48
33. P. Wutzler, K. Wutke, D. Bärwolff, and J. Reefschläger BVDU-Therapie von Zostererkrankungen bei Patienten mit malignem Grundleiden Z gesamte inn Med 43 1988 677 680
34. P.C. Maudgal, E. De Clercq, J. Descamps, L. Missotten, P. De Somer, and R. Busson (E)-5-(2-Bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex keratitis Antimicrob Agents Chemother 17 1980 8 12
35. K.F. Soike, S. Gibson, and P.J. Gerone Inhibition of simian varicella virus infection of African green monkeys by (E)-5-(2-bromovinyl)-2′- deoxyuridine (BVDU) Antiviral Res 1 1981 325 337
36. H.S. Allaudeen, J.W. Kozarich, J.R. Bertino, and E. De Clercq On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2′-deoxyuridine Proc Natl Acad Sci USA 78 1981 2698 2702
37. J. Descamps, and E. De Clercq Specific phosphorylation of E-5-(2-iodovinyl)-2′-deoxyuridine by herpes simplex virus-infected cells J Biol Chem 256 1981 5973 5976
38. P.C. Maudgal, L. Dralands, L. Lamberts, E. De Clercq, J. Descamps, and L. Missotten Preliminary results of oral BVDU treatment of herpes zoster ophthalmicus Bull Soc Beige Ophtalmol 193 1981 49 56
39. E. De Clercq, J. Descamps, M. Ogata, and S. Shigeta In vitro susceptibility of varicella-zoster virus to E-5(-2-bromovinyl)-2′- deoxyuridine and related compounds Antimicrob Agents Chemother 21 1982 33 38
40. W.R. Mancini, E. De Clercq, and W.H. Prusoff The relationship between incorporation of E-5-(2-bromovinyl)-2′-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity J Biol Chem 258 1983 792 795
41. C. Desgranges, G. Razaka, F. Drouillet, H. Bricaud, P. Herdewijn, and E. De Clercq Regeneration of an antiviral drug (E)-5-(2-bromovinyl)-2′- deoxyuridine (BVDU) in vivo Nucl. Acids Res 12 1984 2081 2090
42. E. De Clercq Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds Antimicrob Agents Chemother 26 1984 155 159
43. C. Desgranges, G. Razaka, E. De Clercq, P. Herdewijn, J. Balzarini, and F. Drouillet Effect of (E)-5-(2-bromovinyl)uraci on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice Cancer Res 46 1986 1094 1101
44. G. Tricot, E. De Clercq, M.A. Boogaerts, and R. Verwilghen Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial J Med Virol 18 1986 11 20
45. M. Iigo, Y. Nakajima, A. Hoshi, and E. De Clercq Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice Eur J Cancer Clin Oncol 23 1987 773 777
46. J. Balzarini, E. De Clercq, A. Verbruggen, D. Ayusawa, K. Shimizu, and T. Seno Thymidylate synthetase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene Mol Pharmacol 32 1987 410 416
47. M. Heidi, H. Scholz, W. Dorffel, J. Hermann, and P. Wutzler Vergleichende Priifing der Wirksamkeit von Bromvinyldesoxyuridin und Aciclovir bei Varicella-Zoster-Virus-Infektionen immunsupprimierter Kinder - eine prospektive randomisierte Studie Z Klin Med 45 1990 1259 1262
48. J. Balzarini, C. Bohman, and E. De Clercq Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(2,3-dihydroxy-2-propoxymethyl)-guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2 J Biol Chem 268 1993 6332 6337
49. P. Wutzler, E. De Clercq, K. Wutke, and I. Farber Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial J Med Virol 46 1995 252 257
50. E. De Clercq The antiviral spectrum of (E)-5-(2-bromovinyl)-2′- deoxyuridine J Antimicrob Chemother 14 Suppl A 1984 85 95
51. J. Neyts, and E. De Clercq In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents Antimicrob Agents Chemother 42 1998 170 172
52. J.W. Harkness, J.J. Sands, and I.S. Sim Bovine herpes mammillitis therapy Veterinary Record 118 1986 282
53. G.A. Smith, and J.M. Whalley (E)-5-(2′-Bromovinyl)-2′- deoxyuridine inhibition of macropodid herpesvirus 1 in vitro J. Zoo Wildlife Med 29 1998 157 159
54. G. Smith In vitro sensitivity of macropodid herpesvirus 2 to selected anti-herpetic compounds J Wildlife Dis 32 1996 117 120
55. D. Reymen, L. Naesens, J. Balzarini, A. Holy, H. Dvorakova, and E. De Clercq Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6 Antiviral Res 28 1995 343 357
56. Y. Zhang, D. Schols, and E. De Clercq Selective activity of various antiviral compounds against HHV-7 infection Antiviral Res 43 1999 23 35
57. J. Neyts, and E. De Clercq Antiviral drug susceptibility of human herpesvirus 8 Antimicrob Agents Chemother 41 1997 2754 2756
58. G. Andrei, R. Snoeck, P. Goubau, J. Desmyter, and E. De Clercq Comparative activity of various compounds against clinical strains of herpes simplex virus Eur J Clin Microbiol Infect Dis 11 1992 143 151
59. G. Andrei, R. Snoeck, D. Reymen, C. Liesnard, P. Goubau, and J. Desmyter Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus Eur J Clin Microbiol Infect Dis 14 1995 318 328
60. J. Balzarini, R. Bernaerts, A. Verbruggen, and E. De Clercq Role of the incorporation of (E)-5-(2-iodovinyl)-2′-deoxyuridine and its carbocyclic analogue into DNA of herpes simplex virus type 1-infected cells in the antiviral effects of these compounds Mol Pharmacol 37 1990 402 407
61. J.A. Fyfe Differential phosphorylation of (E)-5-(2-bromovinyl)-2′- deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus Mol Pharmacol 21 1982 432 437
62. N.K. Ayisi, E. De Clercq, R.A. Wall, H. Hughes, and S.L. Sacks Metabolic fate of (E)-5-(2-bromovinyl)-2′-deoxyuridine in herpes simplex virus- and mock-infected cells Antimicrob Agents Chemother 26 1984 762 765
63. P.J. Barr, N.J. Oppenheimer, and D.V. Santi Thymidylate synthetase-catalyzed conversions of E-5-(2-bromovinyl)-2′-deoxyuridylate J Biol Chem 258 1983 13627 13631
64. T. Yokota, K. Konno, and S. Shigeta Inhibition of thymidylate synthetase activity induced in varicella-zoster virus infected cells by (E)-5-(2-bromovinyl)-2′-deoxyuridine Antiviral Chem Chemother 5 1994 191 194
65. B.A. Jennings Wilber, and J.J. Docherty Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2′-deoxyuridine J Gen Virol 75 1994 1743 1747
66. J.W. Gnann Jr., C.S. Crumpacker, J.P. Lalezari, J.A. Smith, S.K. Tyring, K.F. Baum the Collaborative Antiviral Study Group (CASG)/AIDS Clinical Trials Group (ACTG) Herpes Zoster Study Group Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial Antimicrob Agents Chemother 42 1998 1139 1145
67. Wassilew SW, Stubinski BM, Staedtler G, Koch I, Schumacher K, Neubauer A. A randomized, double-blind survey on the effect of brivudin in the prevention of postherpetic pain in comparison with acyclovir. Abstracts of the Fourth International Conference on Varicella, Herpes Zoster and Post-Herpetic Neuralgia, La Jolla, CA, USA, 3-5 March 2001, no. 45.
68. Wassilew SW, Schumacher K, Staedtler G, Koch I, Capriati A, Stubinski BM, Brivudin compared to famciclovir in the prevention of postherpetic neuralgia: a randomized, double-blind multicenter trial. Abstracts of the Fourth International Conference on Varicella, Herpes Zoster and Post-Herpetic Neuralgia, La Jolla, CA, USA, 3-5 March 2001, no. 46.
69. Wassilew SW, Stubinski BM, Koch I, Schumacher K, Stadtler G, Brivudin compared to acyclovir and famciclovir: effect on zoster-associated pain. Abstracts of the 14th International Conference on Antiviral Research, Seattle, WA, USA, 8-13 April 2001. Antiviral Res 2001;50(A90):180.
70. Wassilew SW, Stubinski BM, Koch I, Schumacher K, Stadtler G, Brivudin compared to acyclovir and famciclovir: effect on zoster-associated pain. Abstracts of the 14th International Conference on Antiviral Research, Seattle, WA, USA, 8-13 April 2001. Antiviral Res 2001;50(A90):180.
71. Wassilew SW, Wutzler P, Stubinski BM, Koch I, Staedtler G, Capriati A. Brivudin compared to acyclovir and famciclovir in acute herpes zoster. Abstracts of the CONVIR 2002. European Conference on Viral Diseases, Munich, Germany, 10-12 May 2002. Infection 2002;30(Suppl 1):12, no. 056.
72. Wassilew SW, Wutzler P, Stubinski BM, Koch I, Staedtler G, Capriati A. Brivudin compared to acyclovir and famciclovir in acute herpes zoster. Abstracts of the CONVIR 2002. European Conference on Viral Diseases, Munich, Germany, 10-12 May 2002. Infection 2002;30(Suppl 1):12, no. 056.
73. Wassilew SW, Wutzler P, Stubinski BM, Koch I, Stadtler G, Capriati A. Brivudin compared to acyclovir for the treatment of herpes zoster: effects on acute disease and postherpetic pain. Abstracts of the Fourth European Congress of Chemotherapy and Infection, Paris, France, 5-8 May 2002.
74. Wassilew SW, Stubinski BM, Koch I, Staedtler G, Schumacher K, Capriati A. Oral brivudin for herpes zoster: results of a famciclovir-controlled study in immunocompetent patients > 50 years. Abstracts of the 10th Annual Meeting of the International Herpes Management Forum (HIMF), 28 February-2 March 2003, no. VZV-03.
75. S.W. Wassilew, P. Wutzler on behalf of the Brivudin Herpes Zoster Study Group Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study Antiviral. Res. 59 2003 49 56
76. Wutzler P, Stubinski BM, Koch I, Staedtler G, Schumacher K, Brivudin compared to acyclovir in the treatment of acute herpes zoster: a randomized, double-blind, multicenter trial. Abstracts of the Fourth International Conference on Varicella, Herpes Zoster and Post-Herpetic Neuralgia, La Jolla, CA, USA, 3-5 March 2001, no. 47.
77. Wutzler P, Wassilew SW, Stubinski BM, Koch I, Schumacher K, Staedtler G, Efficacy and safety of brivudin in the treatment of herpes zoster. Abstracts of the 14th International Conference on Antiviral Research, Seattle, WA, USA, 8-13 April 2001. Antiviral Res 2001;50:A69, no. 108.
78. Wutzler P, Wassilew SW, Stubinski BM, Koch I, Schumacher K, Staedtler G, Efficacy and safety of brivudin in the treatment of herpes zoster. Abstracts of the 14th International Conference on Antiviral Research, Seattle, WA, USA, 8-13 April 2001. Antiviral Res 2001;50:A69, no. 108.
79. Wutzler P, Wassilew SW, Stubinski BM, Koch I, Schumacher K, Stadtler G, et al., Efficacy and safety of brivudin in the treatment of herpes zoster. Results of two randomised, controlled clinical trials. Abstracts of the Eighth Western Pacific Congress of Chemotherapy and Infectious Diseases, Perth, Australia, 1-5 December 2002.
80. S.W. Wassilew, P. Wutzler on behalf of the Brivudin Herpes Zoster Study Group Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia Antiviral Res 59 2003 57 60
81. E. De Clercq Antiviral activity of nucleoside analogues: the BVDU connection C.K. Chu Recent advances in nucleosides: chemistry and chemotherapy 2002 Elsevier Science B.V Amsterdam 433 454
82. H.J. Keizer, E.A. De Bruijn, U.R. Tjaden, and E. De Clercq Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine J Cancer Res Clin Oncol. 120 1994 545 549
83. M. Iigo, E. Araki, Y. Nakajima, A. Hoshi, and E. De Clercq Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice Biochem Pharmacol. 37 1988 1609 1613
84. M. Iigo, Nishikata K-i, Y. Nakajima, A. Hoshi, and E. De Clercq Effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases Eur J Cancer 26 1990 1089 1092
85. H. Okuda, T. Nishiyama, Y. Ogura, S. Nagayama, K. Ikeda, and S. Yamaguchi Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs Drug Metab Dispos 25 1997 270 273
86. H. Okuda, K. Ogura, A. Kato, H. Takubo, and T. Watabe A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs J Pharmacol Exp Ther 287 1998 791 799
87. K. Ogura, T. Nishiyama, H. Takubo, A. Kato, H. Okuda, and K. Arakawa Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine Cancer Lett 122 1998 107 113
88. H. Machida, Y. Watanabe, F. Kano, S. Sakata, M. Kumagai, and T. Yamaguchi Deglycosylation of antiherpesviral 5-substituted arabinosyluracil derivatives by rat liver extract and enterobacteria cells Biochem Pharmacol 49 1995 763 766
89. H. Nakayama, T. Kinouchi, K. Kataoka, S. Akimoto, Y. Matsuda, and Y. Ohnishi Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-5-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil Pharmacogenetics 7 1997 35 43
90. J. Yan, S.K. Tyring, M.M. McCrary, P.C. Lee, S. Haworth, and R. Raymond The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster Clin Pharmacol Ther 61 1997 563 573
91. R.B. Diasio Sorivudine and 5-fluorouracil: a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase Br J Clin Pharmacol 46 1998 1 4
92. S-I. Kanamitsu, K. Ito, H. Okuda, K. Ogura, T. Watabe, and K. Muro Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil Drug Metab Dispos 28 2000 467 474
93. T. Nishiyama, K. Ogura, H. Okuda, K. Suda, A. Kato, and T. Watabe Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH Mol Pharmacol 57 2000 899 905
94. O. Weber Novel mouse models for the investigation of experimental drugs with activity against human varicella-zoster virus Antiviral Chem Chemother 11 2000 283 290
95. A.S. Jones, S.G. Rahim, R.T. Walker, and E. De Clercq Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2′-deoxyuridine J Med Chem 24 1981 759 760
96. A.S. Jones, J.R. Sayers, R.T. Walker, and E. De Clercq Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2′-deoxycytidine-related compounds J Med Chem 31 1988 268 271
97. J. Balzarini, E. De Clercq, H. Baumgartner, M. Bodenteich, and H. Griengl Carbocyclic 5-iodo-2′-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2′-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+) and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1 Mol Pharmacol 37 1990 395 401
98. S. Spadari, G. Ciarrocchi, F. Focher, A. Verri, G. Maga, and F. Arcamone 5-Iodo-2′-deoxy-L-uridine and (E)-5-(2-bromovinyl)-2′-deoxy-L- uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity, and cytotoxicity studies Mol Pharmacol 47 1995 1231 1238
99. Choi Ys, L. Li, S. Grill, E. Gullen, C.S. Lee, and G. Gumina Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses J Med Chem 43 2000 2538 2546
100. I. Basnak, G.P. Otter, R.J. Duncombe, N.B. Westwood, M. Pietrarelli, and G.W. Hardy Efficient syntheses of (E)-5-(2-bromovinyl)-2′-deoxy-4′- thiouridine. a nucleoside analogue with potent biological activity Nucleosides Nucleotides 17 1998 29 38
101. B. Degreve, G. Andrei, M. Izquierdo, J. Piette, K. Morin, and E.E. Knaus Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer Gene Ther 4 1997 1107 1114
102. H. Satoh, Y. Yoshimura, M. Watanabe, N. Ashida, K. Ijichi, and S. Sakata Synthesis and antiviral activities of 5-substituted l-(2-deoxy-2-C-methylene-4- thio-β-d-erythro-pentofuranosyl)uracils Nucleosides Nucleotides 17 1998 65 79
103. K. Kitano, H. Machida, S. Miura, and H. Ohrui Synthesis of novel 4′-C-methyl-pyrimidine nucleosides and their biological activities Bioorg Med Chem Lett 9 1999 827 830
104. M.J. Bamford, P.L. Coe, and R.T. Walker Synthesis and antiviral activity of 3′-deoxy-3′-C-hydroxymethyl nucleosides J Med Chem 33 1990 2494 2501
105. E. Ichikawa, S. Yamamura, and K. Kato Synthesis of 2′,3′- dideoxy-3′-C-(hydroxymethyl)-4'-thiopentofuranosyl nucleosides as potential antiviral agent Bioorg Med Chem Lett 9 1999 1113 1114
106. J.A. Tino, J.M. Clark, A.K. Field, G.A. Jacobs, K.A. Lis, and T.L. Michalik Synthesis and antiviral activity of novel isonucleoside analogs J Med Chem 36 1993 1221 1229
107. K.F. Soike, J-L.L. Huang, J.W. Russell, V.J. Whiterock, J.E. Sundeen, and L.W. Stratton Pharmacokinetics and antiviral activity of a novel isonucleoside, BMS-181165, against simian varicella virus infection in African green monkeys Antiviral Res 23 1994 219 224
108. T. Onishi, C. Mukai, R. Nakagawa, T. Sekiyama, M. Aoki, and K. Suzuki Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety J Med Chem 43 2000 278 282
109. S. Guenther, J. Balzarini, E. De Clercq, and V. Nair A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity J Med Chem 45 2002 5426 5429
110. P. Russ, P. Schelling, L. Scapozza, G. Folkers, E. De Clercq, and V.E. Marquez Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine J Med Chem 46 2003 5045 5054
111. E. De Clercq, C. Desgranges, P. Herdewijn, I.S. Sim, A.S. Jones, and M.J. McLean Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine J Med Chem 29 1986 213 217
112. R. Bernaerts, C. Desgranges, and E. De Clercq (E)-5-(2-Bromovinyl)uridine requires phosphorylation by the herpes simplex virus (type l)-induced thymidine kinase to express its antiviral activity Biochem Pharmacol 38 1989 1955 1961
113. S.N. Farrow, A.S. Jones, A. Kumar, R.T. Walker, J. Balzarini, and E. De Clercq Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells J Med Chem 33 1990 1400 1406
114. A. Kumar, P.L. Coe, A.S. Jones, R.T. Walker, J. Balzarini, and E. De Clercq Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives J Med Chem 33 1990 2368 7235
115. E. De Clercq, R.T. Walker, and R.F. Whale 3′-O-benzyl-(E)-5-(2- bromovinyl)-2′-deoxyuridine is active as an anti-herpes agent in vivo but not in vitro Med Chem Res 2 1992 111 118
116. E. De Clercq Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues Med Res Rev 23 2003 253 275
117. R. Sienaert, G. Andrei, R. Snoeck, E. De Clercq, C. McGuigan, and J. Balzarini Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase Biochem. Biophys Res. Commun. 315 2004 877 883
118. G. Gross, H. Schöfer, S. Wassilew, K. Friese, A. Timm, and R. Guthoff Herpes zoster guideline of the German Dermatology Society (DDG) J. Clin. Virol. 26 2003 277 289
119. P. Wutzler, and R. Thust Genetic risks of antiviral nucleoside analogues - a survey Antiviral Res 49 2001 55 74